Ann: Neuren and Acadia expand global partnership for trofinetide, page-51

@Mr_Cod @goldenchook

I found some of the information in slides to be a little unclear. I missed the web conference this morning. They may have explained things better then

The way I read this is:
* Acadia already had the right to use Trof in North America for any indication it wanted to go after - Rett, Syn-X, Others to be identified
* Along comes NEU with NNZ-2591 which seems to be a more effective drug with less side effects than Trof. An open question is that could 2591 be a better drug for Rett and Syn-X than Trof ==>> so a threat to further development of Trof
* NEU already has 4 x Ph2 trials underway for PhelanMcDermid, Pitt Hopkins, Angelman andPrader-Willi syndromes. So these stay with NEU.
* Here is the kicker I think: If Acadia announced tomorrow that it is starting other new IND trials using Trof, then I think that would exclude NEU from starting similar new IND trials using 2591 in these neo conditions in North America

I like the deal as it will now allow NEU to focus more fully on its 4 x 2591 Ph2 trials.

I would like to know what, if any, timeline details are included in this new ROW deal with Acadia.
How quickly will Acadia move to expand outside of North America?
I expect we may not see much action on ROW activity this year.
I think Acadia is likely to wait to see NEU's 2591 data read out late 2023 before it make any major decisions.

Why would Acadia roll out Daybue to ROW if 2591 looks like it could be more effective?
RETT maybe as they already have FDA approval and the data to back it up, so it could be a faster path for more revenue.
Syn-X, I am not so sure as they may wait on 2591 outcome.
Maybe better for Acadia to do a deal with NEU to use 2591 instead of Trof for a Ph2 and Ph3 trial for Syn-X.

GLTA